RICHMOND, Calif., Oct. 17, 2017 /PRNewswire/ --Sangamo
Therapeutics, Inc. (Nasdaq: SGMO) announced today presentations by
Company scientists at the 2017 Annual Congress of the European
Society of Gene and Cell Therapy (ESGCT). The meeting is being held
in Berlin, Germany from
October 17-20th.
The following presentations are scheduled at the 2017 ESGCT
meeting:
- Michael Holmes, Ph.D., VP,
Research, will present an overview of Sangamo's optimized zinc
finger nuclease (ZFN) architectures for therapeutic genome
editing.
Title: New zinc finger nuclease architectures for precision
genome engineering in the development of novel genomic
therapies
Invited Talk – Friday,
October 20th
- Anthony Conway, Ph.D., Sangamo
scientist, will present additional research data on ZFN-mediated
in vivo genome editing using the Company's lipid
nanoparticle delivery platform.
Title: In vivo genome editing via non-viral delivery of zinc
finger nucleases enables supraphysiological levels of therapeutic
proteins and greater than 90% protein knockdown of multiple
therapeutic gene targets via targeted integration and NHEJ,
respectively, in wild type mice
Oral Presentation –
Wednesday, October
18th
- Marshall Huston, Ph.D., Sangamo
scientist, will present an update on the Company's preclinical
stage gene therapy program for Fabry disease.
Title: Liver-based expression of the human
alpha-galactosidase A gene in murine Fabry model results in
continuous high, therapeutic levels of enzyme activity and
effective substrate reduction
Poster Presentation –
Wednesday, October
18th
Webcasting services are not provided at this meeting.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc.
is focused on translating ground-breaking science into genomic
therapies that transform patients' lives using the Company's
industry leading platform technologies in genome editing, gene
therapy, gene regulation and cell therapy. For more information
about Sangamo, visit www.sangamo.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/sangamo-therapeutics-announces-presentations-at-2017-annual-congress-of-the-european-society-of-gene-and-cell-therapy-300538257.html
SOURCE Sangamo Therapeutics, Inc.